The company reported positive Phase 1b results for ATI-052 in AD and asthma, with a strong cash runway extending through 2029; recent catalysts include the initiation of the Phase 2b modzatinib trial in lichen planus and Top Line results from the bosakitug Phase 2 ADMIRATION trial.